|
The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday. ---------- SMALL-CAP - WINNERS ---------- Eco Buildings Group PLC, up 14% at 15.74 pence, 12-month range 2.50p-28.60p. The London-based designer, manufacturer and builder of modular housing completes groundworks at its luxury 18-unit apartment development in Albania’s capital Tirana. Construction of the ground floor is now underway. Eco Buildings expects to generate revenues of €2.2 million for each apartment block, with anticipated gross margins of 40%. To date the company has received deposit payments of €440,000. ---------- Evoke PLC, down 6.2% at 25.65 pence, 12-month range 19.76p-77.80p. The Gibraltar-based betting and gaming operator and owner of the William Hill and 888 brands reports revenue growth of 2% to £1.78 billion in financial 2025 and expects to post 2025 adjusted earnings before interest, tax, depreciation, and amortisation in line with market expectations margin of about 20%. Adjusted Ebitda is expected to come in between £355 million and £360 million, up around 15% from a year prior. Says UK budget ‘dealt significant blow’ to company and wider regulated industry, and that it moved ‘quickly and decisively’ to offset recent budget changes to gambling taxes through shop closures and cost cuts. CEO Per Widerstrom says ‘While the strong strategic and financial progress we made throughout 2025 was encouraging, we were very disappointed with the outcome of the UK budget in November that dealt a significant blow to both evoke and the wider regulated industry. We continue to believe these tax increases will negatively impact the industry’s economic contribution, customer protection, and will ultimately serve to support further growth in the illegal black market. As a result of these significant UK tax increases, the board is assessing its strategic options, with a resolute focus on maximising shareholder value.’ Additionally, analysts at Peel Hunt move their Evoke rating to ’under review’ from ’buy’. ---------- SMALL-CAP - LOSERS ---------- Nuformix PLC, down 18% at 0.23p, 12-month range 0.07p-0.49p. The London-based developer of treatments for fibrosis and oncology narrows pretax loss in the year to September 30 to £660,569 from £3.6 million, while booking no revenue either year. Administrative expenses widen to GBP£660,569 from £506,353. Nuformix says the main priority for directors is to focus on the company’s NXP002 programme and specifically to find a business development partner. NXP002 is Nuformix’s lead asset and novel treatment for progressive pulmonary fibrosis, administered by inhalation. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
